Oncorus, Inc.
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-59.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (755.53% volume)
Earnings Calendar: 2022-11-02
Market Cap: $ 3,287,951
http://www.oncorus.com
Sec Filling | Patents | 56 employees
Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.
cancer immunotherapy
add to watch list Paper trade email alert is off
Press-releases
Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
Published: 2023-07-06 (Crawled : 20:00) - globenewswire.com
ONCSQ | $0.0001 43900.0% 820
|
Manufacturing
|
| O: -15.79%
H: 12.5%
C: -6.25%
CYXTQ | $0.0007 -57.14% 1.8K
|
|
| O: -4.89%
H: 17.73%
C: -5.28%
QTEKQ | $0.012 125.0% 640K
|
Construction
|
| O: -17.88%
H: 11.07%
C: -0.37%
ATNXQ | $0.0152 -85.53% 3.6K
|
Manufacturing
|
| O: 54.31%
H: 0.0%
C: -29.37%
IMVIQ | $0.0001 36400.0% 6K
|
Manufacturing
|
| O: -18.75%
H: 192.31%
C: 32.62%
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -2.05%
H: 29.3%
C: 0.0%
NESR | $8.8 0.0% 7.7K
|
Industrial Services
|
| O: 0.0%
H: 0.0%
C: 0.0%
NDAQ | $60.2 -2.15% -2.19% 3.2M
|
Finance
|
| O: -0.22%
H: 0.8%
C: 0.18%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -14.11%
H: 7.11%
C: 6.2%
management nasdaq energy services beyond group acquisition medical molecular market
Oncorus Announces Workforce Reduction Plan
Published: 2023-06-01 (Crawled : 20:00) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -38.06%
H: 8.99%
C: 1.51%
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-05-22 (Crawled : 20:00) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -20.51%
H: 7.72%
C: -1.56%
business financial results
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Published: 2023-03-24 (Crawled : 12:00) - biospace.com/
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 0.06%
H: 12.8%
C: 5.15%
business year financial results
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Published: 2023-01-04 (Crawled : 21:00) - biospace.com/
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 7.87%
H: 9.73%
C: 0.0%
drug research collaboration mrna
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
Published: 2022-11-30 (Crawled : 13:20) - biospace.com/
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -18.27%
H: 0.0%
C: -3.98%
cancer
Oncorus to Participate in Upcoming Investor Conferences
Published: 2022-11-23 (Crawled : 13:20) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 15.7%
H: 0.0%
C: -14.27%
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
Published: 2022-11-18 (Crawled : 13:20) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 5.3%
H: 7.81%
C: 6.72%
oncr-719 preclinical meeting growth glioblastoma
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
Published: 2022-10-07 (Crawled : 13:20) - globenewswire.com
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 2.41%
H: 4.38%
C: -10.09%
treatment communications cancer publication platform
DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO
Published: 2022-09-27 (Crawled : 13:00) - biospace.com/
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: 2.16%
H: 8.88%
C: 1.21%
biopharma ceo
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10